Early Access — free while we kick the tires
EdgarHawk

Yezan Munther Haddadin

Director

Director

Latest: Director buying · June 2026

2 filings analyzed · 1 company · Latest 2026-06-03

Never miss a filing from Yezan Munther Haddadin

Watch this insider and we'll alert you the moment they file — at any company.

Companies

Company Buys Sells Direction
Outlook Therapeutics, Inc. OTLK 2 0 Net buying

Activity

June 2026
2026-06-03 Outlook Therapeutics, Inc. OTLK Cluster
high
Buy
29,000 shares
$24,145
Significance 6/10

Director Yezan Munther Haddadin bought 29,000 shares of OTLK at $0.83; 4 other insiders bought within 14 days; stock at $0.81, -76.1% from 52-week high.

Director Yezan Munther Haddadin purchased 29,000 shares at $0.83 on 2026-06-02, increasing his holdings to 66,167 shares, a +78.0% increase in position size. The company generated Revenue $1,505,322.00 in the latest quarter but reported Net income $-4,453,081.00 and remains unprofitable on a full-year basis, creating a contrasting backdrop of fundamental weakness. The stock has traded at $0.81 currently, down -76.1% from its 52-week high of $3.39, yet has rallied +208.6% over the past 30 days and +87.6% over 90 days. This filing documents part of a broader cluster: 4 other insiders also bought within the past 14 days, marking a multi-insider transaction pattern during a period of sharp price recovery from cycle lows. His prior buy at this ticker on 2026-05-26 achieved a +84.9% 30-day return and +84.9% 90-day return, demonstrating recent successful prior accumulation at OTLK.

May 2026
low
Buy
34,000 shares
$14,960
Significance 3/10

Director Yezan Munther Haddadin bought 34,000 shares of OTLK at $0.44; stock down 84.7% from 52-week high, insider's 1 prior buy yielded -39.5% 90d return.

Director Yezan Munther Haddadin purchased 34,000 shares at $0.44 on 2026-05-26, increasing his holdings from 3,167 to 37,167 shares. The purchase occurs at depressed absolute levels—the stock is currently $0.52, down 84.7% from its 52-week high of $3.39—but the transaction price of $0.44 is below current levels. Notably, his single prior buy at OTLK on 2024-03-28 resulted in a -39.5% 90-day return, indicating this insider has not demonstrated timing accuracy at this ticker. The company remains unprofitable with a quarterly revenue of $1,505,322.00 and net income of $-4,453,081.00, providing limited fundamental support for accumulation at present price levels.

Related insiders